Home › Funds › E. Ohman J:or Asset Management AB › VRTX

E. Ohman J:or Asset Management AB position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

E. Ohman J:or Asset Management AB reported holding 57,554 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$30.1M, representing 0.67% of its reported portfolio and ranking #34 among its reported holdings. E. Ohman J:or Asset Management AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)57.55K sh
Reported value held$30.09M
Portfolio Weight0.67%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How E. Ohman J:or Asset Management AB's VRTX position evolved

E. Ohman J:or Asset Management AB first disclosed a stake in VRTX in Q3 2023 at 11,900 shares (US$4.1M). The position peaked in Q3 2026 at 57,554 shares, worth US$30.1M. Across 13 filings, E. Ohman J:or Asset Management AB increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 57,554 shares valued at US$30.1M — an increase of 48,731 shares quarter over quarter.. Notable position changes include a 552% increase in Q3 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 11.90K $4.14M New
Q4 2023 10.00K $4.07M Reduce
Q1 2024 10.50K $4.39M Add
Q2 2024 11.06K $5.18M Add
Q3 2024 10.31K $4.79M Reduce
Q4 2024 11.74K $4.73M Add
Q1 2025 11.49K $5.57M Reduce
Q2 2025 10.52K $4.68M Reduce
Q3 2025 10.52K $4.12M Hold
Q4 2025 9.02K $4.09M Reduce
Q1 2026 8.82K $3.94M Reduce
Q2 2026 8.82K $4.38M Hold
Q3 2026 57.55K $30.09M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has E. Ohman J:or Asset Management AB held VRTX?

E. Ohman J:or Asset Management AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is E. Ohman J:or Asset Management AB's current position in VRTX?

As of Q3 2026, E. Ohman J:or Asset Management AB holds 57.55K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $30.09M, representing 0.67% of its reported portfolio and ranking #34.

Has E. Ohman J:or Asset Management AB been buying or selling VRTX?

In the latest 13F filing (Q3 2026), E. Ohman J:or Asset Management AB increased its position in VRTX. The position peaked in Q3 2026 at 57.55K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.